Plain-English translation of NCT06496581 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether adding a medication called 177Lu-PSMA-617 — a radioactive treatment that targets prostate cancer cells — alongside your regular cancer medications can help men whose cancer hasn't responded as well as hoped after 6 to 8 months of standard therapy. Half of participants will continue with standard treatment alone, while the other half will also receive the medication given as injections every 6 weeks for up to 4 cycles. The goal is to see if this treatment helps control the cancer better.
Some men with advanced prostate cancer don't respond well enough to standard treatment alone, even though they've been on it for several months. Researchers believe this radioactive medication might help target and destroy remaining cancer cells in people whose cancer is being stubborn, potentially improving outcomes for these early poor responders.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you'll be randomly assigned to either continue your current standard treatment or to also receive the radioactive medication as injections every 6 weeks for up to 4 cycles. You'll have regular visits to your cancer center for blood work, imaging scans, and to monitor how you're responding — likely every few weeks during active treatment. The trial will follow you for up to 8.5 years after treatment ends to track how well the treatment is working and any side effects. Throughout this time, your medical team will watch your PSA levels and imaging to see how your cancer is responding.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
France